|Bid||33.190 x 2000|
|Ask||33.200 x 10200|
|Day's Range||33.170 - 33.480|
|52 Week Range||29.830 - 37.390|
|PE Ratio (TTM)||27.95|
|Earnings Date||Aug 1, 2017|
|Dividend & Yield||1.28 (3.82%)|
|1y Target Est||37.40|
In 2016, Pfizer’s (PFE) Sutent reported revenues of ~$1.1 billion, which represented a ~2% decline on a YoY (year-over-year) basis.
ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings
ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive interim results from DAWNING. This is a non-inferiority study conducted to compare second-line treatment of the protease inhibitor-sparing regimen of dolutegravir and 2 nucleoside reverse transcriptase inhibitors (NRTIs), with a current WHO-recommended regimen of lopinavir/ritonavir and 2 NRTIs in HIV-1-infected adults. The study's Independent Data Monitoring Committee (IDMC) noted significant and clinically-relevant differences between treatment arms in favour of dolutegravir and recommended that the boosted lopinavir treatment arm be discontinued.